Atlas Trials

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

Clinical trial NCT05271162 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05271162
Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Cardiotoxicity
Start date
2023-09-30
Primary completion
2028-01-01
Enrollment
220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.